Evidence map›Paper›PMID 34112698›Full record

ArticleCancer discovery2021

Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History.

Livius Penter, Satyen H Gohil, Caleb Lareau, Leif S Ludwig, Erin M Parry, Teddy Huang, Shuqiang Li, Wandi Zhang, Dimitri Livitz, Ignaty Leshchiner and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Livius Penter *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9060-0207
Satyen H Gohil *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Caleb LareauBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0003-4179-4807
Leif S LudwigBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Erin M ParryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3382-9769
Teddy HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wandi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dimitri LivitzBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0003-2528-1446
Ignaty LeshchinerBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Laxmi ParidaIBM TJ Watson Research Center, Yorktown Heights, New York, New York.ORCID 0000-0002-7872-5074
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0002-0936-0753
Laura Z RassentiMoores Cancer Center, University of California San Diego, La Jolla, California.
Thomas J KippsMoores Cancer Center, University of California San Diego, La Jolla, California.
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2566-3145
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-9105-5856
Vijay G SankaranBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3348-5054
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USUniversity of California San Diego · USIBM Research - Thomas J. Watson Research Center · US

Funding

Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4M
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
Single Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI KIM, HAESOOK T · 2019 to 2023
$13.8M
Personal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6M
Systematic Genetic Dissection of Human ErythropoiesisR01DK103794 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Vijay Ganesh Sankaran · 2014 to 2026
$5.9M
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)R01CA258924 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2021 to 2025
$3.1M
Unlocking the Potential of PI3K Inhibition in CLLR01CA213442 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2017 to 2021
$2.9M
Statistical methods for analysis of single-cell variabilityR01HL131768 · NHLBI · HARVARD MEDICAL SCHOOL · PI KHARCHENKO, PETER V · 2015 to 2019
$2.4M
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4M
NCI NIH HHS P01 CA206978NCI NIH HHS P01 CA229092NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA213442NCI NIH HHS R01 CA258924NCI NIH HHS R50 CA251956NCI NIH HHS U24 CA224331NCI NIH HHS UG1 CA233338NHLBI NIH HHS R01 HL131768NIDDK NIH HHS R01 DK103794
6 · The paper itself

Abstract

While cancers evolve during disease progression and in response to therapy, temporal dynamics remain difficult to study in humans due to the lack of consistent barcodes marking individual clones in vivo. We employ mitochondrial single-cell assay for transposase-accessible chromatin with sequencing to profile 163,279 cells from 9 patients with chronic lymphocytic leukemia (CLL) collected across disease course and utilize mitochondrial DNA (mtDNA) mutations as natural genetic markers of cancer clones. We observe stable propagation of mtDNA mutations over years in the absence of strong selective pressure, indicating clonal persistence, but dramatic changes following tight bottlenecks, including disease transformation and relapse posttherapy, paralleled by acquisition of copy-number variants and changes in chromatin accessibility and gene expression. Furthermore, we link CLL subclones to distinct chromatin states, providing insight into nongenetic sources of relapse. mtDNA mutations thus mirror disease history and provide naturally occurring genetic barcodes to enable patient-specific study of cancer subclonal dynamics. SIGNIFICANCE: Single-cell multi-omic profiling of CLL reveals the utility of somatic mtDNA mutations as in vivo barcodes, which mark subclones that can evolve over time along with changes in accessible chromatin and gene expression profiles to capture dynamics of disease evolution. See related commentary by Hilton and Scott, p. 2965. This article is highlighted in the In This Issue feature, p. 2945.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellChromatinClonal EvolutionClone CellsDNA Copy Number VariationsHumansMutationChromatin

Identifiers

PMID34112698
PMCPMC8660953
OpenAlexW3169699851

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.